Dry powder inhaler system

a technology of inhaler and powder, which is applied in the direction of respirator, transportation and packaging, packaging, etc., can solve the problems of retarding capsule dissolution, discolouration or formation of crosslinks between gelatin and gelatin, and not being suitable for use with water-sensitive drugs or drug compositions, etc., and achieves the effect of facilitating envelope piercing

Inactive Publication Date: 2006-11-16
GALEPHAR PHARMA RES
View PDF6 Cites 59 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0025] According to a preferred embodiment, the piercing systems are bevel-edged needles or pins. This enables an easier piercing of the envelope, even if the diameter of the piercing pin is larger.

Problems solved by technology

In capsule shells made from gelatin, the main material used for this purpose generally contains 13-15% water and therefore may not be suitable for use with water sensitive drugs or drug composition.
Some drugs may react with the amino groups of gelatin, causing discolouration or formation of crosslinks between gelatin molecules which retard capsule dissolution.
As said, the main disadvantages of hard gelatin capsules are their relatively high water content (13-16%), their animal origin, their brittleness characteristics and the fact that they may chemically or physically interact with some active or inactive ingredients.
When the moisture content of the capsule shell is decreased, as may occur when a desiccant is added to a package of capsules containing moisture-labile drugs, gelatin capsules tend to become brittle and are subject to breakage during transport and storage.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dry powder inhaler system
  • Dry powder inhaler system
  • Dry powder inhaler system

Examples

Experimental program
Comparison scheme
Effect test

example 1

Formoterol DPI Formulation

[0073] Formoterol fumarate is a well known long acting bronchodilator used in the treatment of asthma. Formoterol has been formulated in DPI with the formula given herebelow (Table 2) and then the powder was filled into either hard gelatin capsules or HPMC capsules. The FPD of formoterol obtained from each type of capsule is given in Table 3. (The definition of the FPD is given in the European Pharmacopoeia, 3rd edition, chapter 2.9.18. Briefly, the FPD is the dose (expressed in unity of mass) of the drug presenting a diameter below 5.0 μm when a formulation is tested on an Impactor)

[0074] The average (average in weight) particle size of the formoterol containing powder was about 3 μm (median Gauss range: about 2 to 4 μm, i.e. 50% by weight of the particles have a size comprised between about 2 μm and about 4 μm).

TABLE 2DPI formulation of formoterol fumarate DPImg / capsulemicronized formoterol fumarate0.012lactose23.988TOTAL24.000

[0075] The in-vitro depo...

example 2

Budesonide

[0091] Budesonide is a corticosteroid derivative very widely used in the treatment of asthma. A comparison between a DPI formulation of budesonide (see table 5) filled into HPMC capsules and hard gelatin capsules, and administered respectively with the four pins devices and the single pin device, has been made.

[0092] The in-vitro deposition tests have been realized as follows: [0093] Impactor: Multistage Liquid Impinger [0094] Airflow: 100 L / min [0095] Volume of air: 4 liters [0096] DPI device: four pins device or single pin device [0097] 3 capsules / test

[0098] The tests and calculations have been performed in accordance with Eur. Ph., 3rd ed., 2.9.18.

[0099] The formulations of budesonide tested are described in Table 4. The average (average in weight) particle size of the micronized budesonide powder was about 3 μm (median Gauss range: about 2 to 4 μm, i.e. 50% by weight of the particles have a size comprised between about 2 μm and about 4 μm).

TABLE 5formulation of b...

example 3

Salmeterol

[0103] A DPI formulation containing 50 μg of salmeterol base (under the form of salmeterol xinafoate and 24.950 mg of lactose, has been filed into HPMC capsules. A MLI test has been performed on those capsules administered with the single pin device and the results were compared to the results obtained with a marketed salmeterol DPI formulation of salmeterol (Serevent®, Diskus®, Glaxo Smithkline). Each device was used at the airflow recommended by the european Pharmacopoeia 4th edition i.e 100 L / min for the single pin device and 80 L / min for the Serevent® Diskus®. The results obtained with

TABLE 7comparative in vitro deposition of salmeterol DPIformulations + single pin device versus Serevent ® Diskus ®(MLI, n = 3)FPD (ug)MMADGSDmean ± SDmean ± SDmean ± SDSalmeterol DPI + single17.87 ± 0.682.69 ± 0.051.37 ± 0.02pin deviceSerevent Diskus 7.89 ± 0.532.98 ± 0.041.38 ± 0.01

[0104] The results clealry demonstrate that the FPD is much higher (more than twice as high) for the sa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An improved dry powder inhalation system comprising: at least one micronized active ingredient in an hydroxypropylmethylcellulose capsule (10), and an dry powder inhaler device equipped with piercing systems (12) having an equivalent diameter of not less than 0.8 mm.

Description

[0001] The present invention relates to a pharmaceutical composition for inhalation, consisting in a combination of (A) a dry powder formulation containing a micronized active ingredient, alone or mixed with an inactive ingredient, said powder being filled in a hydroxypropylmethylcellulose (HPMC) capsule and (B) a single dose dry powder inhaler device especially adapted to said capsule to provide a high respiratory dose of said active ingredient when said drug is inhaled by the mouth through said device. Said device being characterized in that he is equipped with piercing needles or pins (in order to pierce the capsule) of diameter of not less than 0.8 mm preferably not less than 1 mm. BACKGROUND [0002] Capsules, and essentially hard gelatin capsules are very widely used in the pharmaceutical industry to allow oral administration of drugs. [0003] Hard gelatin capsules were developed as an edible container to mask the taste and odour of medicines. As a result of the introduction of m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61M15/00A61M16/10A61K9/00
CPCA61K9/0075A61M15/0033A61M2202/064A61M15/0028A61M15/0021A61M15/0035
Inventor DEBOECK, ARTHURBAUDUER, PHILIPPE
Owner GALEPHAR PHARMA RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap